Substances that are recognized by the immune system and induce an immune reaction.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Substances elaborated by bacteria that have antigenic activity.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Substances elaborated by viruses that have antigenic activity.
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary thymocytes, granulocytes, macrophages, erythrocytes, and fibroblasts. CD44 antigens are the principle cell surface receptors for hyaluronate and this interaction mediates binding of lymphocytes to high endothelial venules. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Differentiation antigens expressed on pluripotential hematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.
Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including monocytes, macrophages, and some granulocytes. They function as receptors for the complex of lipopolysaccharide (LPS) and LPS-binding protein.
Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
Ratio of T-LYMPHOCYTES that express the CD4 ANTIGEN to those that express the CD8 ANTIGEN. This value is commonly assessed in the diagnosis and staging of diseases affecting the IMMUNE SYSTEM including HIV INFECTIONS.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.
Antibodies produced by a single clone of cells.
The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.
Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
A membrane-bound or cytosolic enzyme that catalyzes the synthesis of CYCLIC ADP-RIBOSE (cADPR) from nicotinamide adenine dinucleotide (NAD). This enzyme generally catalyzes the hydrolysis of cADPR to ADP-RIBOSE, as well, and sometimes the synthesis of cyclic ADP-ribose 2' phosphate (2'-P-cADPR) from NADP.
Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukemias and lymphomas.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Tetraspanin proteins found at high levels in cells of the lymphoid-myeloid lineage. CD53 antigens may be involved regulating the differentiation of T-LYMPHOCYTES and the activation of B-LYMPHOCYTES.
A cell adhesion protein that was originally identified as a heat stable antigen in mice. It is involved in METASTASIS and is highly expressed in many NEOPLASMS.
Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.
A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin.
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Substances of fungal origin that have antigenic activity.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The major group of transplantation antigens in the mouse.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
Cell-surface glycoprotein beta-chains that are non-covalently linked to specific alpha-chains of the CD11 family of leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE-ADHESION). A defect in the gene encoding CD18 causes LEUKOCYTE-ADHESION DEFICIENCY SYNDROME.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Glycoproteins found on the membrane or surface of cells.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Sites on an antigen that interact with specific antibodies.
A subtype of tetraspanin proteins that play a role in cell adhesion, cell motility, and tumor metastasis. CD9 antigens take part in the process of platelet activation and aggregation, the formation of paranodal junctions in neuronal tissue, and the fusion of sperm with egg.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.
Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.
Established cell cultures that have the potential to propagate indefinitely.
A sialic acid-rich protein and an integral cell membrane mucin. It plays an important role in activation of T-LYMPHOCYTES.
Leukocyte differentiation antigens and major platelet membrane glycoproteins present on MONOCYTES; ENDOTHELIAL CELLS; PLATELETS; and mammary EPITHELIAL CELLS. They play major roles in CELL ADHESION; SIGNAL TRANSDUCTION; and regulation of angiogenesis. CD36 is a receptor for THROMBOSPONDINS and can act as a scavenger receptor that recognizes and transports oxidized LIPOPROTEINS and FATTY ACIDS.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A group of three different alpha chains (CD11a, CD11b, CD11c) that are associated with an invariant CD18 beta chain (ANTIGENS, CD18). The three resulting leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE ADHESION) are LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MACROPHAGE-1 ANTIGEN; and ANTIGEN, P150,95.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
Small glycoproteins found on both hematopoietic and non-hematopoietic cells. CD59 restricts the cytolytic activity of homologous complement by binding to C8 and C9 and blocking the assembly of the membrane attack complex. (From Barclay et al., The Leukocyte Antigen FactsBook, 1993, p234)
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
Oligosaccharide antigenic determinants found principally on NK cells and T-cells. Their role in the immune response is poorly understood.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; and DENDRITIC CELLS where it plays a role in stimulating the proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES.
A ubiquitously expressed complement receptor that binds COMPLEMENT C3B and COMPLEMENT C4B and serves as a cofactor for their inactivation. CD46 also interacts with a wide variety of pathogens and mediates immune response.
A class of animal lectins that bind to carbohydrate in a calcium-dependent manner. They share a common carbohydrate-binding domain that is structurally distinct from other classes of lectins.
Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
A ubiquitously expressed membrane glycoprotein. It interacts with a variety of INTEGRINS and mediates responses to EXTRACELLULAR MATRIX PROTEINS.
A CD antigen that contains a conserved I domain which is involved in ligand binding. When combined with CD18 the two subunits form MACROPHAGE-1 ANTIGEN.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
An integrin alpha subunit of approximately 150-kDa molecular weight. It is expressed at high levels on monocytes and combines with CD18 ANTIGEN to form the cell surface receptor INTEGRIN ALPHAXBETA2. The subunit contains a conserved I-domain which is characteristic of several of alpha integrins.
The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Progenitor cells from which all blood cells derive.
The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
GPI-linked membrane proteins broadly distributed among hematopoietic and non-hematopoietic cells. CD55 prevents the assembly of C3 CONVERTASE or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex.
Cell adhesion molecules present on virtually all monocytes, platelets, and granulocytes. CD31 is highly expressed on endothelial cells and concentrated at the junctions between them.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
Tetraspanin proteins that are involved in a variety of cellular functions including BASEMENT MEMBRANE assembly, and in the formation of a molecular complexes on the surface of LYMPHOCYTES.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Proteins prepared by recombinant DNA technology.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.
Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
Ubiquitously-expressed tetraspanin proteins that are found in late ENDOSOMES and LYSOSOMES and have been implicated in intracellular transport of proteins.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Tetraspanin proteins found associated with LAMININ-binding INTEGRINS. The CD151 antigens may play a role in the regulation of CELL MOTILITY.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
An encapsulated lymphatic organ through which venous blood filters.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
A membrane-bound tumor necrosis family member found primarily on activated T-LYMPHOCYTES that binds specifically to CD30 ANTIGEN. It may play a role in INFLAMMATION and immune regulation.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A class of enzymes involved in the hydrolysis of the N-glycosidic bond of nitrogen-linked sugars.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
An alpha-integrin subunit found on lymphocytes, granulocytes, macrophages and monocytes. It combines with the integrin beta2 subunit (CD18 ANTIGEN) to form LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
A widely distributed cell surface transmembrane glycoprotein that stimulates the synthesis of MATRIX METALLOPROTEINASES. It is found at high levels on the surface of malignant NEOPLASMS and may play a role as a mediator of malignant cell behavior.
A general term for various neoplastic diseases of the lymphoid tissue.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
A widely expressed transmembrane glycoprotein that functions as a METASTASIS suppressor protein. It is underexpressed in a variety of human NEOPLASMS.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
A cell line derived from cultured tumor cells.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.
A cell adhesion molecule of the immunoglobulin superfamily that is expressed in ENDOTHELIAL CELLS and is involved in INTERCELLULAR JUNCTIONS.
Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
Antibodies obtained from a single clone of cells grown in mice or rats.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
A heterodimeric protein that is a cell surface antigen associated with lymphocyte activation. The initial characterization of this protein revealed one identifiable heavy chain (ANTIGENS, CD98 HEAVY CHAIN) and an indeterminate smaller light chain. It is now known that a variety of light chain subunits (ANTIGENS, CD98 LIGHT CHAINS) can dimerize with the heavy chain. Depending upon its light chain composition a diverse array of functions can be found for this protein. Functions include: type L amino acid transport, type y+L amino acid transport and regulation of cellular fusion.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
The sum of the weight of all the atoms in a molecule.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
Immunoglobulins produced in response to VIRAL ANTIGENS.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.
Elements of limited time intervals, contributing to particular results or situations.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
An inhibitory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN. CD274 antigen provides negative signals that control and inhibit T-cell responses and is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).

Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. (1/4274)

Angiosarcomas apparently derive from blood vessel endothelial cells; however, occasionally their histological features suggest mixed origin from blood and lymphatic endothelia. In the absence of specific positive markers for lymphatic endothelia the precise distinction between these components has not been possible. Here we provide evidence by light and electron microscopic immunohistochemistry that podoplanin, a approximately 38-kd membrane glycoprotein of podocytes, is specifically expressed in the endothelium of lymphatic capillaries, but not in the blood vasculature. In normal skin and kidney, podoplanin colocalized with vascular endothelial growth factor receptor-3, the only other lymphatic marker presently available. Complementary immunostaining of blood vessels was obtained with established endothelial markers (CD31, CD34, factor VIII-related antigen, and Ulex europaeus I lectin) as well as podocalyxin, another podocytic protein that is also localized in endothelia of blood vessels. Podoplanin specifically immunolabeled endothelia of benign tumorous lesions of undisputed lymphatic origin (lymphangiomas, hygromas) and was detected there as a 38-kd protein by immunoblotting. As paradigms of malignant vascular tumors, poorly differentiated (G3) common angiosarcomas (n = 8), epitheloid angiosarcomas (n = 3), and intestinal Kaposi's sarcomas (n = 5) were examined for their podoplanin content in relation to conventional endothelial markers. The relative number of tumor cells expressing podoplanin was estimated and, although the number of cases in this preliminary study was limited to 16, an apparent spectrum of podoplanin expression emerged that can be divided into a low-expression group in which 0-10% of tumor cells contained podoplanin, a moderate-expression group with 30-60% and a high-expression group with 70-100%. Ten of eleven angiosarcomas and all Kaposi's sarcomas showed mixed expression of both lymphatic and blood vascular endothelial phenotypes. By double labeling, most podoplanin-positive tumor cells coexpressed endothelial markers of blood vessels, whereas few tumor cells were positive for individual markers only. From these results we conclude that (1) podoplanin is a selective marker of lymphatic endothelium; (2) G3 angiosarcomas display a quantitative spectrum of podoplanin-expressing tumor cells; (3) in most angiosarcomas, a varying subset of tumor cells coexpresses podoplanin and endothelial markers of blood vessels; and (4) all endothelial cells of Kaposi's sarcomas expressed the lymphatic marker podoplanin.  (+info)

Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. (2/4274)

Angiogenesis is essential for tumor growth and metastasis. There are conflicting reports as to whether microvessel density (IMD) in breast cancers is associated with prognosis. This could be due to the use of different antibodies to endothelial cell markers, variation in tissue pretreatment protocols, and nonstandardized counting methods. We have assessed the IMD in 106 breast carcinomas using a pan-endothelial marker, CD34, and a recently described mAb to CD105, which preferentially reacts with endothelial cell in angiogenic tissues. IMD values (separated as above or below median) for CD105 expression showed a statistically significant correlation with overall (P = 0.0029) and disease-free survival (P = 0.0362). In contrast, blood vessel counts using a panendothelial marker CD34 did not correlate with overall or disease-free survival (P = 0.2912 and P = 03153, respectively). When IMD values were subdivided into quartiles and assessed for their prognostic values, there was a statistically significant difference in the overall survival across CD105, but not CD34, values (P = 0.0017 and P = 0.7997, respectively) and also disease-free survival (P = 0.0431 and P = 0.5066, respectively). Further analysis of IMD values demonstrated that there were no deaths in the lowest quartile for CD105 and it differed from the other three quartiles. However, examination of clinical details of patients in the lowest quartile failed to reveal clustering of patients known to be associated with low-risk factors. Multivariate analysis confirmed that IMD values using CD105 were an independent prognostic factor. These results suggest that the ability to quantitatively distinguish between tumor neovascularization and preexisting vessels may be important in the assessment of tumor angiogenesis, but requires confirmation in a greater number of patients with a longer follow-up.  (+info)

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. (3/4274)

We have evaluated the immunophenotype, functional activity and clonogenic potential of CD34+ cells from peripheral blood (PB) of normal donors before and after 4 and 6 days of G-CSF administration. The percentage and absolute number of CD34+ cells significantly increased at days 4 and 6 of G-CSF administration, compared to the steady-state level (P < 0.0001). Two-colour fluorescence analysis showed, at days 4 and 6, a lower proportion of CD34+/c-kit+ compared to the steady-state level (P < 0.0001), but a similar expression of CD13, CD33, CD38, HLA-DR and Thy-1 antigens on CD34+ cells. The expression of adhesion molecules on CD34+ cells revealed a significant reduction of CD11a (P = 0.009), CD18, CD49d and CD62L (P < 0.0001) at days 4 and 6, compared to the baseline level. Three-colour staining showed a reduction of the more immature compartment (34+/DR-/13-) and an increase of the more differentiated compartment (34+/DR+/13+). Downregulation of VLA-4 during mobilisation was seen almost exclusively on more committed cells (34+/13+); downregulation of CD62L, on the contrary, was observed on both early progenitors (34+/13-) and more committed cells (34+/13+). The expression of 34+/VLA-4+ decreased on both c-kit+ and c-kit- cells, while the expression of 34+/62L+ decreased on the c-kit+ cells only. In vivo administration of G-CSF reduced the adherence capacity of CD34+ cells to normal BM stroma; in vitro incubation with SCF or IL-3 enhanced the expression of CD49d on CD34+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34+ cell adherence to preformed stroma. Pre-incubation with the blocking beta2 integrin monoclonal antibody caused a reduction of CD34+ cell adherence. In conclusion, the decrease of CD49d expression on mobilized CD34+ cells correlates with a poor adhesion to BM stroma; CD34+ cells incubated in vitro with SCF showed, conversely, a higher expression of CD49d and a greater adherence capacity on normal preformed stroma.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (4/4274)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. (5/4274)

High-dose chemotherapy followed by autologous transplantation has been shown to improve response rates and survival in multiple myeloma and other malignancies. However, autografts frequently contain detectable tumor cells. Enrichment for stem cells using anti-CD34 antibodies has been shown to reduce autograft tumor contamination in phase I/II studies. To more definitively assess the safety and efficacy of CD34 selection, a phase III study was completed in 131 multiple myeloma patients randomized to receive an autologous transplant with either CD34-selected or unselected peripheral blood progenitor cells after myeloablative therapy. Tumor contamination in the autografts was assessed by a quantitative polymerase chain reaction detection assay using patient-specific, complementarity-determining region (CDR) Ig gene primers before and after CD34 selection. A median 3.1 log reduction in contaminating tumor cells was achieved in the CD34 selected product using the CEPRATE SC System (CellPro, Inc, Bothell, WA). Successful neutrophil engraftment was achieved in all patients by day 15 and no significant between-arm difference for time to platelet engraftment occurred in patients who received an infused dose of at least 2.0 x 10(6) CD34(+) cells/kg. In conclusion, this phase III trial demonstrates that CD34-selection of peripheral blood progenitor cells significantly reduces tumor cell contamination yet provides safe and rapid hematologic recovery for patients receiving myeloablative therapy.  (+info)

Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. (6/4274)

We evaluated the capacity of adeno-associated virus (AAV) vectors to transduce primitive human myeloid progenitor cells derived from marrow and cord blood in long-term cultures and long-term culture-initiating cell (LTC-IC) assays. Single-colony analyses showed that AAV vectors transduced CD34(+) and CD34(+)38(-) clonogenic cells in long-term culture. Gene transfer was readily observed in LTC-ICs derived from 5-, 8-, and 10-week cultures. Recombinant AAV (rAAV) transduction was observed in every donor analyzed, although a wide range of gene transfer frequencies (5% to 100%) was noted. AAV transduction of LTC-ICs was stable, with week-8 and -10 LTC-ICs showing comparable or better transduction relative to week-5 LTC-ICs. Fluorescence in situ hybridization (FISH) analyses performed to determine the fate of AAV vectors in transduced cells showed that 9% to 28% of CD34(+) and CD34(+)38(-) cells showed stable vector integration as evidenced by chromosome-associated signals in metaphase spreads. Comparisons of interphase and metaphase FISH suggested that a fraction of cells also contained episomal vector at early time points after transduction. Despite the apparent loss of the episomal forms with continued culture, the number of metaphases containing integrated vector genomes remained stable long term. Transgene transcription and placental alkaline phosphatase (PLAP) expression was observed in CD34(+), CD34(+)38(-) LTC-ICs in the absence of selective pressure. These results suggest that primitive myeloid progenitors are amenable to genetic modification with AAV vectors.  (+info)

Cyclin A1 expression in leukemia and normal hematopoietic cells. (7/4274)

Human cyclin A1 is a newly cloned, tissue-specific cyclin that is prominently expressed in normal testis. In this study, we showed that cyclin A1 was highly expressed in a subset of leukemia samples from patients. The highest frequency of cyclin A1 overexpression was observed in acute myelocytic leukemias, especially those that were at the promyelocyte (M3) and myeloblast (M2) stages of development. Cyclin A1 expression was also detected in normal CD34(+) progenitor cells. The expression of cyclin A1 increased when these cells were stimulated to undergo myeloid differentiation in vitro. Taken together, our observations suggest that cyclin A1 may have a role in hematopoiesis. High levels of cyclin A1 expression are especially associated with certain leukemias blocked at the myeloblast and promyelocyte stages of differentiation.  (+info)

Detection of small numbers of immature cells in the blood of healthy subjects. (8/4274)

AIMS: To determine the frequency of immature haemopoietic cells in the peripheral blood of healthy persons. METHODS: Cytocentrifuge preparations were made using mononuclear leucocytes separated by a Ficoll-Hypaque density gradient. The slides were stained by May-Grunwald-Giemsa. The combination with immunoperoxidase technique allowed immunotyping of uncommon blood cells. RESULTS: Blast cells expressing the progenitor cell marker CD34 represented 0.11 (0.06) per cent (mean (SD)) of the total mononuclear leucocyte count; these were the haemopoietic progenitor cells in the peripheral blood. Dark blue cells expressing CD38, CD45, HLA-DR, CD4, CD11a, CD29, CD49d, CD50, and CD54 represented 0.30 (0.21) per cent of the mononuclear leucocytes; most of these cells did not express T, B, NK, myelomonocytic, progenitor cell, proliferation, activation, blood dendritic cell, or follicular dendritic cell markers. These were dendritic cell precursors in the peripheral blood. Very small numbers of cells expressing CD83 were found. Blast-like cells expressing CD45, HLA-DR, CD11a, and CD50 represented 0.15 (0.10) per cent of the mononuclear leucocytes; morphology and immunotyping supported the conclusion that these cells were poorly differentiated monocytes. CONCLUSIONS: Morphological investigation of mononuclear leucocytes in peripheral blood of healthy persons can be used to detect small numbers of blasts, dark blue cells, and blast-like cells. The immunoperoxidase technique can then be used for immunotyping of these cells. This simple method may be helpful in diagnosing haematological disorders.  (+info)

TY - JOUR. T1 - Decreased homing of retrovirally transduced human bone marrow CD34 + cells in the NOD/SCID mouse model. AU - Hall, Kristin M.. AU - Horvath, Tamara L.. AU - Abonour, Rafat. AU - Cornetta, Kenneth. AU - Srour, Edward F.. PY - 2006/4/1. Y1 - 2006/4/1. N2 - Objective. Many clinical gene therapy trials have described poor engraftment of retrovirally transduced CD34+ cells. Because engraftment is dependent upon successful homing of graft cells to the bone marrow (BM), we examined whether retroviral-mediated gene transfer (RMGT) induces a homing defect in CD34+ cells. Methods. Homing of fluorescently labeled human BM CD34+ cells transduced with three separate retroviral vectors (MFG-eGFP, LNC-eGFP, and LXSN) was assessed in nonobese diabetic/severe combined immunodeficient mice. Results. Homing of transduced CD34+ cells was significantly decreased 20 hours after transplantation compared with freshly isolated control and cultured untransduced control cells. Specifically, homing of GFP+ ...
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience ...
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...
Background: CD31, PECAM-1 has been used as a marker for endothelial cells. However, recent data have indicated that CD31 is also expressed at an early developmental stage. We hypothesized that CD31 could serve as a comprehensive epitope to encircle various subsets of hemangioblastic cells in adult bone marrow (BM).. Methods and Results: A fraction of CD31+ cells of BM mononuclear cells in C57BL/6 mice co-expressed well known stem cell markers including c-kit, Sca-1, and flk-1. The expression levels of these markers were distinct when hematopoietic lineage positive cells were depleted (Lin−) from CD31+ cells. Moreover, Lin−CD31+ cells exclusively expressed genes characterizing pluripotency such as Oct4, Rex4, Nanog, and SSEA-1.A microarray revealed that CD31+ cells expressed multiple angiogenic genes compared to CD31− cells. In particular, only a CD31+ but not CD31− fraction gave rise to endothelial progenitor cells (EPCs) in a culture assay. To determine in vivo activity, we performed BM ...
Top 10 tissues for NP_776216 (Homo sapiens, RefSeq): peripheral blood anergic B-cell, peripheral blood CD4 resting T-cell (unspecified), peripheral blood CD4 memory regulatory T-cell, peripheral blood CD4 naive regulatory T-cell, tumor derived CD4 T-cell (unspecified), peripheral blood CD4 memory T-cell (unspecified), peripheral blood CD8 activated T-cell (unspecified), tonsillar activated T-cell (unspecified), bone marrow CD4 T-cell (unspecified), gingival epithelium organotypic model
title: Impaired function and epigenetic changes of human cord blood-derived CD133+/C-kit+Lin- endothelial progenitor cells in preeclampsia, doi: none, category: Thesis
TY - JOUR. T1 - Drosophila forkhead homologues are expressed in CD34+HLA-DR- primitive human hematopoietic progenitors. AU - Hromas, Robert. AU - Klemsz, Michael. AU - Amaravadi, Lakshmi. AU - Hufford, Tricia. AU - Huang, Irene. AU - Desai, Alpana. AU - Srour, Edward. AU - Bruno, Edward. AU - Hoffman, Ronald. PY - 1994. Y1 - 1994. N2 - The Forkhead gene (FKH) regulates morphogenesis in Drosophila. It is the prototype of a new family of transcriptional activators. We used the polymerase chain reaction (PCR) to analyze the expression pattern of this new transcriptional regulatory gene family in primitive hematopoeitic progenitors. Partially degenerate oligonucleotides to two conserved amino acid sequences of this family were used to prime a PCR amplification of cDNA synthesized from CD34+HLA-DR- hematopoietic cells. Known and novel FKH genes were found to be expressed in these cells.. AB - The Forkhead gene (FKH) regulates morphogenesis in Drosophila. It is the prototype of a new family of ...
TY - JOUR. T1 - Upregulation of IL-5 receptor expression on bone marrow-derived CD34+ cells from patients with asthma.. AU - Chou, C. L.. AU - Wang, C. H.. AU - Kuo, H. P.. PY - 1999/1/1. Y1 - 1999/1/1. N2 - BACKGROUND: Interleukin-5 (IL-5) is a potent eosinophilopoietic factor implicated in the chronic inflammatory cell accumulation accompanying bronchial asthma. We studied the expression of the IL-5 receptor alpha-subunit (IL-5R alpha) on bone marrow-derived cluster of differentiation molecule 34 positive (CD34+) progenitor cells in asthmatics to prove the ability of progenitor cells to respond to IL-5 more readily. METHODS: Non-adherent non-T cells (NANT) were separated from heparinized bone marrow blood from 6 asthmatics and 3 normal subjects, loaded with CD34+ and IL-5R alpha monoclonal antibodies conjugated with immunofluorescence and then analyzed by flow cytometry. Colonies grown from progenitor cells cultured in methylcellulose were determined for 14 days in the presence or absence of ...
Hematopoiesis depends on the association of hematopoietic stem cells with stromal cells that constitute the hematopoietic microenvironment. The in vitro development of the endothelial cell from umbilical cord blood (UCB) is not well established and has met very limited success. In this study, UCB CD34(+) cells were cultured for 5 weeks in a stroma-free liquid culture system using thrombopoietin, flt3 ligand, and granulocyte-colony stimulating factor. By week 4-5, we found that firmly adherent fibroblast-like cells were established. These cells showed characteristics of endothelial cells expressing von Willebrand factor, human vascular cell adhesion molecule-1, human intracellular adhesion molecule-1, human CD31, E-selectin, and human macrophage. Furthermore, when comparing an ex vivo system without an established endothelial monolayer to an ex vivo system with an established endothelial monolayer, better expansion of total nucleated cells, CD34(+) cells, and colony-forming units ...
TY - JOUR. T1 - Generation and function of progenitor t cells from stemregenin-1-expanded CD34+ human hematopoietic progenitor cells. AU - Singh, Jastaranpreet. AU - Chen, Edward L.Y.. AU - Xing, Yan. AU - Stefanski, Heather E.. AU - Blazar, Bruce R.. AU - Zúñiga-Pflücker, Juan Carlos. PY - 2019. Y1 - 2019. N2 - Broader clinical application of umbilical cord blood (UCB), as a source of hematopoietic stem/progenitor cells (HSPCs), is limited by low CD34+ and T-cell numbers, contributing to slow lymphohematopoietic recovery, infection, and relapse. Studies have evaluated the safety, feasibility, and expedited neutrophil recovery associated with the transplantation of CD34+ HSPCs from ex vivo expansion cultures using the aryl hydrocarbon receptor antagonist StemRegenin-1 (SR1). In a phase 1/2 study of 17 patients who received combined SR1-expanded and unexpanded UCB units, a considerable advantage for enhancing T-cell chimerism was not observed. We previously showed that progenitor T (proT) ...
Several studies have previously demonstrated enrichment in primitive progenitor cells in subfractions of CD34+bone marrow (BM) cells not expressing CD38 or HLA-DR (DR) antigens. However, no studies have directly compared these two cell populations with regard to their content of primitive and more committed progenitor cells. Flow cytometric analysis of immunomagnetic isolated CD34+cells demonstrated little overlap between CD34+CD38-and CD34+DR-progenitor subpopulations in that only 12% to 14% of total CD34+DR-and CD34+CD38-cells were double negative (CD34+CD38-DR-). Although the number of committed myeloid progenitor cells (colony- forming units granulocyte-macrophage) was reduced in both subpopulations, only CD34+CD38-cells were significantly depleted in committed erythroid progenitor cells (burst-forming units-erythroid). In single-cell assay, CD34+CD38-cells showed consistently poorer response to single as opposed to multiple hematopoietic growth factors as compared with unfractionated CD34+cells,
AllCells offers a wide selection of human primary cells and related products including Bone Marrow CD34+ Stem/Progenitor Cells from our store.
The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigens expressed on non-hematopoietic tumor cells. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and optionally tumor cells. The process involves reacting the sample with an antibody composition containing antibodies capable of binding to the antigens glycophorin A, CD3 CD24, CD16, and CD14, and optionally CD45RA, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigen expressed on non-hematopoietic tumor cells under conditions so that cell conjugates are formed between the antibodies and differentiated cells having the antigens glycophorin A, CD3 CD24, CD16, and CD14, and optionally CD45RA, CD38,
AllCells offers a wide selection of human primary cells and related products including Bone Marrow CD105+ Endothelial Cells from our store.
CD133 is a novel 5-transmembrane cell surface antigen with a molecular weight of 117 kDa. CD133/2 (AC141) antibodies recognize epitope 2 of the human CD133 antigen (CD133/2). In the hematopoietic system, CD133 expression is restricted to a subset of CD34bright stem and progenitor cells in human fetal liver, bone marrow, cord blood and peripheral blood. Additionally, CD133 is expressed by a small portion of CD34- cells in these tissues. The CD34+ CD133+ cell population, which includes CD34+ CD38- cells, was shown to be capable of repopulating NOD/SCID mice. Recently, CD133 has also been found to be expressed on endothelial precursor cells and fetal neural stem cells as well as on developing epithelium. The putative murine homologue, prominin, which is expressed on neuroepithelial and epithelial mouse cells, was identified. In contrast to the other CD133 clones, the clone AC141 shows cross-reactivity with the intracellular protein cytokeratin 18. - USA
CD133 is a novel 5-transmembrane cell surface antigen with a molecular weight of 117 kDa. CD133/2 (AC141) antibodies recognize epitope 2 of the human CD133 antigen (CD133/2). In the hematopoietic system, CD133 expression is restricted to a subset of CD34bright stem and progenitor cells in human fetal liver, bone marrow, cord blood and peripheral blood. Additionally, CD133 is expressed by a small portion of CD34- cells in these tissues. The CD34+ CD133+ cell population, which includes CD34+ CD38- cells, was shown to be capable of repopulating NOD/SCID mice. Recently, CD133 has also been found to be expressed on endothelial precursor cells and fetal neural stem cells as well as on developing epithelium. The putative murine homologue, prominin, which is expressed on neuroepithelial and epithelial mouse cells, was identified. In contrast to the other CD133 clones, the clone AC141 shows cross-reactivity with the intracellular protein cytokeratin 18. - USA
Our leukapheresis products are typically sourced from healthy donors and contain 5-20 billion white blood cells, plasma, platelets & few red blood cells.
Giannoni, Francesca and Hardee, Cinnamon L. and Wherley, Jennifer et al. (2013) Allelic Exclusion and Peripheral Reconstitution by TCR Transgenic T Cells Arising From Transduced Human Hematopoietic Stem/Progenitor Cells. Molecular Therapy, 21 (5). pp. 1044-1054. ISSN 1525-0016. PMCID PMC3666644. ...
ABCell-Bio offers its CD133+ hematopoietic progenitors carefully isolated from umbilical cord blood, an excellent alternative source of Hematopoietic Stem Cells. Our CD133+ hematopoietic progenitors are subject to many quality controls, certifying their virologic compliance, performance, purity and viability. We can supply CD133 + cells with a purity above 95%.
in Transfusion (1998), 38(2), 199-208. BACKGROUND: A study of CD34+ cell selection and transplantation was carried out with particular emphasis on characteristics of short- and long-term hematopoietic recovery. STUDY DESIGN AND METHODS ... [more ▼]. BACKGROUND: A study of CD34+ cell selection and transplantation was carried out with particular emphasis on characteristics of short- and long-term hematopoietic recovery. STUDY DESIGN AND METHODS: Peripheral blood stem and progenitor cells (PBPCs) were collected from 32 patients, and 17 CD34+ cell-selection procedures were carried out in 15 of the 32. One patient in whom two procedures failed to provide 1 x 10(6) CD34+ cells per kg was excluded from further analysis. After conditioning, patients received CD34+ cells (n = 10, CD34 group) or unmanipulated (n = 17, PBPC group) PBPCs containing equivalent amounts of CD34+ cells or progenitors. RESULTS: The yield of CD34+ cells was 53 percent (18-100) with a purity of 63 percent (49-82). The CD34+ ...
TY - JOUR. T1 - Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning. T2 - The effect of postgrafting mycophenolate mofetil dosing. AU - Maris, Michael B.. AU - Sandmaier, Brenda M.. AU - Storer, Barry E.. AU - Maloney, David G.. AU - Shizuru, Judith A.. AU - Agura, Edward. AU - Kliem, Constanze. AU - Pulsipher, Michael. AU - Maziarz, Richard T.. AU - McSweeney, Peter A.. AU - Wade, James. AU - Langston, Amelia A.. AU - Chauncey, Thomas R.. AU - Bruno, Benedetto. AU - Blume, Karl G.. AU - Storb, Rainer. PY - 2006/4/1. Y1 - 2006/4/1. N2 - We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m2, 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg ...
CFU-GM - Colony-Forming Unit-Granulocyte and Monocyte. Looking for abbreviations of CFU-GM? It is Colony-Forming Unit-Granulocyte and Monocyte. Colony-Forming Unit-Granulocyte and Monocyte listed as CFU-GM
Hematopoietic stem/progenitor cells (HSPCs) maintain the hematopoietic system by balancing their self-renewal and differentiation events. Hematopoietic stem cells also migrate to various sites and interact with their specific microenvironment to maintain the integrity of the system. Rho GTPases have been found to control the migration of hematopoietic cells and other cell types. Although the role of RAC1, RAC2 and CDC42 has been studied, the role of RHOA in human hematopoietic stem cells is unclear. By utilizing constitutively active and dominant negative RHOA, we show that RHOA negatively regulates both in vitro and in vivo migration and dominant negative RHOA significantly increased the migration potential of human HSC/HPCs. Active RHOA expression favors the retention of hematopoietic stem/progenitor cells in the niche rather than migration and was found to lock the cells in the G0 cell cycle phase thereby affecting their long-term self-renewal potential. The current study demonstrates that down
Recent developments of surrogate assays for human hematopoietic stem cells (HSC) have facilitated efforts at improving HSC gene transfer efficiency. Through the use of xenograft transplantation models, such as nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, successful oncoretroviral gene transfer to transplantable hematopoietic cells has been achieved. However, because of the low frequency and/or homing efficiency of SCID repopulating cells (SRC) in bone marrow (BM), studies have primarily focused on cord blood (CB). The recently developed extended (| 60 days) long-term culture-initiating cell (ELTC-IC) assay detects an infrequent and highly quiescent candidate stem cell population in BM as well as CB of the CD34(+)CD38(-) phenotype. Although these characteristics suggest that ELTC-IC and SRC might be closely related, attempts to oncoretrovirally transduce ELTC-IC have been unsuccessful. Here, recently developed conditions (high concentrations of SCF + FL + Tpo in serum-free medium)
The only curative therapy for sickle cell disease (SCD) is allogeneic hematopoietic stem cell (HSC) transplantation. Gene therapy approaches for autologous HSC transplantation are being developed. Although earlier engraftment is seen when cells from GCSF-mobilized blood are transplanted than when bone marrow is transplanted, administration of GCSF to patients with SCD can cause significant morbidity. We tested whether primitive hematopoietic progenitors are spontaneously mobilized in the blood of patients with SCD during acute crisis (AC-SCD patients). The frequency of myeloid-lymphoid-initiating cells (ML-ICs) and SCID-repopulating cells (SRCs) was significantly higher in blood from AC-SCD patients than in blood from patients with steady-state SCD or from normal donors. The presence of SRCs in peripheral blood was not associated with detection of long-term culture-initiating cells, consistent with the notion that SRCs are more primitive than long-term culture-initiating cells. As ML-ICs and ...
Human umbilical cord blood derived CD34+ stem cells are reported to mediate therapeutic effects in stroke animal models. Estrogen was known to protect against ischemic injury. The present study wished to investigate whether the protective effect of CD34+ cells against ischemic injury can be reinforced with complemental estradiol treatment in female ovariectomized rat and its possible mechanism. Experiment 1 was to determine the best optimal timing of CD34+ cell treatment for the neuroprotective effect after 60-min middle cerebral artery occlusion (MCAO). Experiment 2 was to evaluate the adjuvant effect of 17β-estradiol on CD34+ cell neuroprotection after MCAO. Experiment 1 showed intravenous infusion with CD34+ cells before MCAO (pre-treatment) caused less infarction size than those infused after MCAO (post-treatment) on 7T magnetic resonance T2-weighted images. Experiment 2 revealed infarction size was most significantly reduced after CD34+ + estradiol pre-treatment. When compared with no treatment
Since tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and transforming growth factor (TGF)-beta have all been shown to be specific inhibitors of early human hematopoiesis, we wanted to investigate the interactions of these three cytokines on very primitive human adult bone marrow CD34++CD38- hematopoietic progenitor cells, using a pre-colony-forming cell (pre-CFC) assay, which detects the effects of these cytokines on the initial phases of the differentiation of these primitive progenitors, which are unresponsive to interleukin (IL) 3 alone. Surprisingly, TNF-alpha was a very potent stimulator of the proliferation of CD34++CD38- cells and was the most potent synergistic factor for the IL-3-induced proliferation of these cells of all cytokines tested (IL-1, IL-6, granulocyte colony-stimulating factor, kit ligand). TNF-alpha was the only cytokine that, as a single added factor, induced substantial proliferation in CD34++CD38- cells in the presence of IL-3, except for kit ligand, which ...
This study enumerated CD45hi/CD34+ and CD45hi/CD133+ human hematopoietic stem cells (HSC) and granulocyte-monocyte colony forming (GM-CFC) progenitor cells in blood and trochanteric and femoral bone marrow in 233 individuals. (SP) multipotential HSC, that are the precursors of CD45hi/CD133+ and CD45hi/CD34+, decline with age. Potentially the increases in stem cell frequencies in the intermediate compartment between SP and GM progenitor cells observed in this study represent a compensatory increase for the loss of more potent members of the HSC hierarchy. testis cause a decline in germ cell self-renewal 40. To test the hypothesis, 233 human subjects, of ages between 21 and 88 years, undergoing hip replacement surgery were enrolled in an IRB approved research which enumerated the SP HSC, Compact disc34+ and Compact disc133+ HSC by movement cytometry and myeloid colony developing cells (GM-CFC) in tradition through the bone marrow from the trochanteric area from the femoral diaphysis and femoral ...
Megan D. Hoban, Gregory J. Cost, Matthew C. Mendel, Zulema Romero, Michael L. Kaufman, Alok V. Joglekar, Michelle Ho, Dianne Lumaquin, David Gray, Georgia R. Lill, Aaron R. Cooper, Fabrizia Urbinati, Shantha Senadheera, Allen Zhu, Pei-Qi Liu, David E. Paschon, Lei Zhang, Edward J. Rebar, Andrew Wilber, Xiaoyan Wang, Philip D. Gregory, Michael C. Holmes, Andreas Reik, Roger P. Hollis, Donald B. Kohn. ...
Holmes, T., Yan, F., Ko, K.-H., Nordon, R., Song, E., OBrien, T. A. and Dolnikov, A. (2012), Ex vivo expansion of cord blood progenitors impairs their short-term and long-term repopulating activity associated with transcriptional dysregulation of signalling networks. Cell Proliferation, 45: 266-278. doi: 10.1111/j.1365-2184.2012.00813.x ...
Expression of Thy-1 on hematopoietic cells from human fetal liver (FL), cord blood (CB), and bone marrow (BM) was studied with a novel anti-Thy-1 antibody, 5E10. Specificity of 5E10 for human Thy-1 was demonstrated by immunoprecipitation of a 25-35-kD molecule, and the sequence of a cDNA that was cloned by immunoselection of COS cells transfected with a cDNA library derived from a 5E10+ cell line. Two- and three-color immunofluorescence staining experiments revealed that the Thy-1 expression is restricted to, an average, 1-4% of FL, CB, and BM cells, and binding to these cell types is essentially restricted to a very small subset of lymphoid cells and approximately 25% of CD34+ cells. Thy-1+ CD34+ cells were further characterized as CD38lo/CD45RO+/CD45RA-/CD71lo/c-kit(lo) and rhodamine 123dull. When CD34+ cells were sorted on the basis of Thy-1 expression, the majority of clonogenic cells were recovered in the CD34+Thy-1- fraction, whereas the majority of cells capable of producing myeloid ...
Oxidative metabolism and redox signaling prove to play a decisional role in controlling adult hematopoietic stem/progenitor cells (HSPCs) biology. However, HSPCs reside in a hypoxic bone marrow microenvironment raising the question of how oxygen metabolism might be ensued. In this study, we provide for the first time novel functional and molecular evidences that human HSPCs express myoglobin (Mb) at level comparable with that of a muscle-derived cell line. Optical spectroscopy and oxymetry enabled to estimate an O-2-sensitive heme-containing protein content of approximately 180 ng globin per 10(6) HSPC and a P-50 of approximately 3 mu M O-2. Noticeably, expression of Mb mainly occurs through a HIF-1-induced alternative transcript (Mb-V/Mb-N = 35 +/- 15, p , .01). A search for other Mb-related globins unveiled significant expression of neuroglobin (Ngb) but not of cytoglobin. Confocal microscopy immune detection of Mb in HSPCs strikingly revealed nuclear localization in cell subsets expressing ...
PURPOSE: To support multicyclic, dose-intensive chemotherapy, we assessed the effects of reinfusing hematopoietic progenitors collected at each cycle in leukapheresis product or whole blood. PATIENTS AND METHODS: Twenty-five patients with small-cell lung cancer (SCLC) were treated with six cycles of ifosfamide, carboplatin, and etoposide (ICE) with granulocyte colony-stimulating factor (G-CSF) 300 micrograms/d subcutaneously (SC) on days 4 to 15. Hematopoietic progenitors collected during each cycle were reinfused on day 3 of the next cycle. Cohort 1 (n = 6) was treated every 3 weeks, with leukapheresis after 2 weeks and cryopreservation of the leukapheresis product. Chemotherapy was given if the WBC count was , or = 3 x 10(9)/L and platelet count , or = 100 x 10(9)/L. Cohort 2 (n = 7) was treated every 2 weeks, with leukapheresis on day 1 of the next cycle and storage of the leukapheresis product at 4 degrees C. Cohort 3 (n = 12) was treated every 2 weeks, with 500 to 750 mL of blood drawn by ...
Hematopoietic progenitor cells, cord blood is used for blood cell transplantation procedures in patients with disorders that affect blood production. This medicine is derived from human blood that is collected from the umbilical cord and placenta. The hematopoietic progenitor cells go to the bone marrow where they become red blood cells, white blood cells, or platelets. These cells enter the blood stream and help restore low blood counts in patients with blood disorders. ...
Abstract. Evidence has been provided recently that shows that high concentrations of cytokines can fulfill functions previously attributed to stromal cells, su
AABB Hematopoietic Progenitor Cell (HPC) activities include educational programs, publications and accreditation for HPC programs.. The list of AABB Accredited HPC Facilities specifies those HPC facilities, in the US and throughout the world, which have attained AABB accreditation. These facilities are responsible for procuring, processing and storing hematopoietic progenitor cells that can be used for transplantation.. ...
The CD109 antigen is a monomeric glycosyl phosphatidylinositol (GPI)-linked glycoprotein of 170 kDa that contains several N-linked endoglycosidase H-sensitive hybrid-type glycans but no O-linked glycan. It has been reported as a novel member of the α2 macroglobulin (α2M) / C3, C4, C5 family of thioester-containing proteins. The CD109 antigen is found on vascular endothelial cells, some epithelial cells, activated, but not resting, T-cells, activated, but not resting, platelets, leukemic megakaryoblasts and a subset of bone marrow CD34+ cells. This antigen is not expressed on fresh peripheral blood lymphocytes (PBL). Poorly differentiated (CD34+, TdT+, CD7+) T-acute leukemias and rare cases of chronic myeloid leukemia in megakaryoblast crisis express the CD109 antigen. Furthermore, megakaryoblastoid cell lines (MO7e, MOLM-1) are CD109+. The CD109 antigen, strongly expressed on KG1a cell line with 20,000 binding sites per cell, may represent a very early marker for hematopoietic cells committed ...
Expression of major cytochrome P450 forms (P450) was followed in preparation of purified hematopoietic CD34+ stem and progenitor cells. Levels of transcripts as well as mature proteins were traced by quantitative real-time polymerase chain reaction and by Northern and Western blotting. P450 1B1 and …
Figure 1: Comparative Analysis of the Hematopoietic Progenitor Cells from Placenta, Cord Blood, and Fetal Liver, Based on Their Immunophenotype
Detailed drug Information for hematopoietic progenitor cells, cord blood Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details ...
Research proven mouse monoclonal CD34 antibody. Excellent marker for hematopoietic progenitors and stem cells. CD34 protein is involved in differentiating HPCs into certain types of neurons. Also useful for studying endothelial cells, angigogensis and tumorigenesis. Designed for immunohistochemisitry and related applications. IHC image available.
Abrupt occlusion of coronary arteries causes MI, which leads to massive cardiomyocyte loss and consequently deterioration of cardiac function because cardiomyocytes have severely limited capacity to be divided and thus replace the damaged tissue. Progressive heart failure is a major cause of death or frequent hospitalization in patients after MI. Although MI is classified as vascular (coronary artery) disease, therapeutic strategies should be focused on regenerating not only blood vessels but also cardiac muscle to improve the poor prognosis of the disease.. Compelling evidence suggests that transplantation of bone marrow-derived CD34+ cells or cultured EPC-enriched population contributes to preservation of LV function after MI through enhancing ischemic neovascularization.10-12 The mechanism of this therapeutic effect was previously considered to be incorporation, differentiation, and proliferation of EPCs for new blood vessel formation.9,11,26 Recently, Badorff et al27 reported in vitro ...
The CD123 antigen, alias Interleukin-3 alpha receptor (IL-3Rα), belongs to the cytokine receptor family. It is constitutively expressed by committed hematopoietic stem / progenitor cells, by most of the myeloid lineage (CD13+, CD14+, CD33+, CD15low), and by some CD19+ cells, it is absent from CD3+ cells ...
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...
Mobilized peripheral blood cells expressing the CD133 (AC133, Prominin-1) marker are generally known as primitive hematopoietic stem and progenitor cells (HSC and HPC).
Human Hematopoietic Stem Cell Expansion Cytokine Bundle contains the key components required for ex vivo Human Hematopoietic Stem Cell.
PRC2 Inhibition Counteracts the Culture-Associated Loss of Engraftment Potential of Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells
Assisted Reproductive Technologies and Haematopoietic stem cells Improvements for Quality and Safety throughout Europe ̶ an European Joint Action ...c
Laboratory equipment supplier for research and industry needs. Access now to the largest scientific products database in our online store.
Combined Growth Factors Enhance the Angiogenic Potential of Human Cord Blood-Derived Mononuclear Cells Transplanted to Ischemic Limbs
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Anti_Human CD45RA_PE_Cy5_conjugate \ CD45RAPC-100 for more molecular products just contact us
Gomes I, Sharma TT, Edassery S, Fulton N, Mar BG, Westbrook CA (Jun 2002). "Novel transcription factors in human CD34 antigen- ...
2002). "Novel transcription factors in human CD34 antigen-positive hematopoietic cells". Blood. 100 (1): 107-19. doi:10.1182/ ...
CD34+CD16/32hi Megakaryocyte-erythroid progenitor (MEP): lin−SCA-1−c-kit+CD34−CD16/32low For HSCs, CD150+CD48− was sufficient ... White Cell Differentiation Antigens: 654-55. Loken MR, Shah VO, Civin CI (1987). "Characterization of myeloid antigens on human ... hematopoietic cell surface antigen defined by a monoclonal antibody raised against KG-1a cells". Journal of Immunology. 133 (1 ... For human HSCs use of CD133 was one step ahead as both CD34+ and CD34− HSCs were CD133+. Traditional purification method used ...
The blasts react with antibodies to myeloperoxidase and antibodies to CD13, CD33, and CD34. Human leukocyte antigen (HLA)-DR is ... but immunophenotyping demonstrates myeloid antigens. In acute myeloblastic leukemia (M0), the blasts are agranular and ...
"Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in ...
Sca-1 is a murine hematopoietic stem cell antigen. Lin is a series of lineage marker antigens that identify mature murine blood ... in murine cultures show phenotypic markers as being CD34-, CD150+, and Flt3- for LTR [long-term reconstitution]. Kit (CD117) is ...
DC-like antigen-presenting cells obtained from human induced pluripotent stem cells can serve as a source for vaccination ... Red blood cells (RBC)s generated in vitro from mobilized CD34 positive cells have normal survival when transfused into an ... Thus, the ability to generate platelet products ex vivo and platelet products lacking HLA antigens in serum-free media would ... A potentially efficient approach for generating antigen-specific CTLs is to revert mature immune T cells into iPSCs, which ...
The tumour cells are generally negative for CD117, DOG1, SMA, Caldesmon, CD34, Epithelial membrane antigen (EMA), Cytokeratin ...
... s typically express vimentin, cytokeratins, epithelial membrane antigen, and CD34, whereas they are usually ... Adoptive immunotherapy seeks to expand a population of the body's T-cells that will recognize a specific tumor antigen. T-cells ... They can also include the administration of laboratory-produced antibodies specific to tumor antigens to create or boost an ... Vaccines can deliver various tumor-associated factors (tumor antigens) to the immune system, resulting in a natural antibody ...
They also lack the expression of markers CD14, CD34, CD45, which can be important in the ability of stromal cells to remain ... Low levels of human leukocyte antigen (HLA-DR) make MSC's hypoimmunogenic. MSC's have trilineage differentiation where they are ...
2005). "Endomucin, a CD34-like sialomucin, marks hematopoietic stem cells throughout development". Journal of Experimental ... Li G, Miles A, Line A, Rees RC (March 2004). "Identification of tumour antigens by serological analysis of cDNA expression ...
... the hematopoietic mucin-like family of molecules that includes leukosialin/CD43 and stem cell antigen CD34; the lysosomal/ ... "MACROPHAGE ANTIGEN CD68; CD68". Retrieved 16 September 2017. Leong, Anthony S-Y; Cooper, Kumarason; Leong, F Joel W-M ... Other names or aliases for this gene in humans and other animals include: CD68 Molecule, CD68 Antigen, GP110, Macrosialin, ... "Macrophage/histiocytic antigen CD68 expression in neoplastic and reactive lymph nodes". Roczniki Akademii Medycznej W ...
Bonnet and Dick isolated a subpopulation of leukemia cells that expressed surface marker CD34, but not CD38. The authors ... stage-specific embryonic antigen-1), EGFR and CD44. The use of CD133 for identification of brain tumor stem-like cells may be ... Markers most frequently used for CSC isolation include: CD133 (also known as PROM1), CD44, ALDH1A1, CD34, CD24 and EpCAM ( ... The cell surface receptor interleukin-3 receptor-alpha (CD123) is overexpressed on CD34+CD38- leukemic stem cells (LSCs) in ...
... known as their human leukocyte antigen (HLA) types. Bone marrow transplants require a complete match on six key antigens, which ... CD34), and bacterial and fungal growth. After the collection, the cord blood unit is shipped to the lab and processed, and then ... It will also be examined for nucleated cell count, cell viability, blood group antigen ABO & Rh blood group system, molecule ... and tissue typing to determine Human Leukocyte Antigen type. ...
... are extracted from the person and purified so that only CD34-expressing cells remain. Those cells are cultured with cytokines ... for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available. The treatment is personalized ...
... since part of them is positive for the CD34 antigen. The classical mast cell markers include the high-affinity IgE receptor, ... The antigen cross-links the FcεR1 molecules, and Lyn tyrosine kinase phosphorylates the ITAMs in the FcεR1 β and γ chain in the ... This antigen stimulated phosphorylation causes the activation of other proteins in the FcεR1-mediated signaling cascade. An ... The Fc region of immunoglobulin E (IgE) becomes bound to mast cells and basophils and when IgE's paratopes bind to an antigen, ...
... antigens, cd30 MeSH D23.050.301.264.035.131 - antigens, cd31 MeSH D23.050.301.264.035.134 - antigens, cd34 MeSH D23.050.301.264 ... antigens, cd30 MeSH D23. - antigens, cd31 MeSH D23. - antigens, cd34 MeSH D23. - ... antigens, cd15 MeSH D23.101.100.900.131 - antigens, cd31 MeSH D23.101.100.920 - antigens, ly MeSH D23.101.100.930 - antigens, ... forssman antigen MeSH D23.050.285.018 - antigens, cd24 MeSH D23.050.285.025 - antigens, cd30 MeSH D23.050.285.040 - antigens, ...
Antigen Antigenicity Immunogen Superantigen Allergen Hapten Epitope Linear Conformational Mimotope Tumor antigen Antigen- ... SLAMF9 Cadherins Selectins E-selectin L-selectin P-selectin Others Lymphocyte homing receptors CD34 GLYCAM-1 Addressin (MAdCAM- ... T cells Antigen receptor - T cell receptor (TCR) Subunits - [email protected] / [email protected] / [email protected] / [email protected] Co-receptors CD8 (CD8α / CD8β) CD4 ... CD18 Macrophage-1 antigen (CR3) - Heterodimer: CD11b / CD18 Integrin alphaXbeta2 (CR4) - Heterodimer: CD11c / CD18 Very late ...
Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146". J. Pathol. 206 (3): 260-8. doi: ... This antigen along with other blood group antigens was used to identify the Basque people as a genetically separate group.[49] ... Because the Duffy antigen is uncommon in those of Black African descent, the presence of this antigen has been used to detect ... The Fy4 antigen, originally described on Fy (a-b-) RBCs, is now thought to be a distinct, unrelated antigen and is no longer ...
Both CD34 and CD33 cells function via the TNFα pathway. Mature activated cytotoxic CD8+ T cells vetoeing involves ligation of ... This means that T-cells with a T-cell receptor specific to antigens presented on the veto cell, bind to the veto cell, and are ... To name some of these cell types; CD34 cells, CD33 cells, CD8 T cells, Immature dendritic cells and NK cells among others. ... The veto cell need only carry the self-MHC determinant or self-MHC determinant plus antigen. Veto-induced tolerance can be ...
Antigens,+CD34 at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... CD34 derives its name from the cluster of differentiation protocol that identifies cell surface antigens. CD34 was first ... CD34 CD34 molecule". Simmons DL, Satterthwaite AB, Tenen DG, Seed B (Jan 1992). "Molecular cloning of a cDNA encoding CD34, a ... CD34 has been shown to interact with CRKL. It also interacts with L-selectin, important in inflammation. CD34- has been related ...
It is considered a major marker of HSC pluripotency in concordance with CD34. In human HSCs, Thy1 cells are all CD34 positive. ... It was originally named theta (θ) antigen, then Thy-1 (THYmocyte differentiation antigen 1) due to its prior identification in ... The antigen Thy-1 was the first T cell marker to be identified. Thy-1 was discovered by Reif and Allen in 1964 during a search ... Reif AE, Allen JM (1964). "The AKR thymic antigen and its distribution in leukemias and nervous tissue". J. Exp. Med. 120 (3): ...
... need to enter secondary lymph nodes to encounter their antigen. Central memory T-lymphocytes, which have encountered antigen, ... CD34, found on endothelial cells. MadCAM-1, found on endothelial cells of gut-associated lymphoid tissue. PSGL-1, binds with ... Here they reside ready to proliferate upon re-encountering antigen. Effector memory T-lymphocytes do not express L-selectin, as ... 1998). "Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34". J. ...
"Identification of genes expressed in human CD34(+) hematopoietic stem/progenitor cells by expressed sequence tags and efficient ... Sperm-associated antigen 7 is a protein that in humans is encoded by the SPAG7 gene. GRCh38: Ensembl release 89: ... PDBe-KB provides an overview of all the structure information available in the PDB for Human Sperm-associated antigen 7 v t e. ... "Entrez Gene: SPAG7 sperm associated antigen 7". CS1 maint: discouraged parameter (link) Suzuki Y, Yamashita R, Shirota M, ...
White Cell Differentiation Antigens. Oxford University Press. Knapp, W; et al. (1989). Leucocyte Typing IV. Oxford University ... For example, a "CD34+, CD31−" cell is one that expresses CD34, but not CD31. This CD combination typically corresponds to a ... "CD Antigens" (PDF). abcam. 2009. Retrieved 2014-11-22. Passlick B, Flieger D, Ziegler-Heitbrock HW (1989). "Identification and ... In the example of CD4 & CD8, these molecules are critical in antigen recognition. Others (e.g., CD135) act as cell surface ...
Retikulinsko barvanje ali imunohistokemija na CD 34 pomagata prepoznati trabekularni vzorec.[1]. *Psevdožlezni ali acinarni ... Kanalikularen vzorec se lahko opazi pri imunohistokemičnem barvanju s poliklonalnimi protitelesi za karcinoembrionalni antigen ... Navadno je negativen na keratine 19 in 20 in epitelijski mebranski antigen.[1] ... vključno z imunohistokemično pozitivnimi CD 34, s faktorjem VII povezanim antigenom, subendotelijskim lamininom in kolagenom ...
T cells become activated by recognising foreign antigens bound to antigen presenting cells (APC), in particular, dendritic ... The rolling mechanism helps the L-selectin molecules on the surface of naive T cells to weakly interact with GlyCAM-1 and CD34 ... Since antigen levels are usually low, contact in blood circulation would be unlikely. Therefore, T cells need a region where ... When an APC, such as a dendritic cell, binds a foreign antigen it becomes activated and moves into the lymph nodes (sites for ...
... Hematopoietic progenitor cell antigen CD34 also known as CD34 antigen is a protein that in humans is encoded by the CD34 ... CD34 CD34 molecule".. *^ Simmons DL, Satterthwaite AB, Tenen DG, Seed B (Jan 1992). "Molecular cloning of a cDNA encoding CD34 ... Cells expressing CD34 (CD34+ cell) are normally found in the umbilical cord and bone marrow as hematopoietic cells, or in ... Antigens, CD34 at the US National Library of Medicine Medical Subject Headings (MeSH) ...
At the end of the 1980s the three-dimensional structure of human leukocyte antigen (HLA) molecule was defined in parallel to ... He further generated monoclonal antibodies specific for the hematopoietic stem cell marker, CD34. A joint collaboration with ... These data clearly demonstrated vaccine-specific immune responses with a broad specter of T cell response against antigens ... Hospital and Baxter resulted in development of an instrument to isolate hematopoietic stem cells in large scale using anti-CD34 ...
... jer dio njih je pozitivan za CD34 antigen. Klasični mastocitni markeri uključuju visoku sklonost za IgE receptor, CD117 (c-Kit ... Antigen unakrsno povezuje molekule FcεR1 i Lyn-tirozin kinazu, u citoplazmi fosforilira u ITAM i b i g FcεR1 lanac. Nakon ... Osim toga, oni imaju zajednički prekursor u koštanoj srži, ispoljen u vidu CD34 molekula. Bazofili napuštaju koštanu srž kada ... Mastocitoza je čest klonski poremećaj mastocita, koji uključuju prisustvo previše mastocita i CD34 + mastocitnih prekursora.[28 ...
CD34 • CD35 • CD36 • CD37 • CD38 • CD39 • CD40 • CD41 • CD42 (a, b, c, d) • CD43 • CD44 • CD45 • CD46 • CD47 • CD48 • CD49 (a, ... 2000). "Characterization of a new member of the TNF family expressed on antigen presenting cells.". Biol. Chem. 380 (12): 1443- ... "BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells.". Semin ...
I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by ... Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... CD30+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ... results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Molecular Immunology. 31 (17): ...
Macrophage-1 antigen (CD11b+CD18). *VLA-4 (CD49d+CD29). *Glycoprotein IIb/IIIa (ITGA2B+ITGB3) ...
Seligman P. A., Butler C. D., Massey E. J., etal. The p97 antigen is mapped to the q24-qter region of chromosome 3; the same ... Le Beau M. M., Diaz M. O., Plowman G. D., etal. Chromosomal sublocalization of the human p97 melanoma antigen. (англ.) // Hum. ... Plowman G. D., Brown J. P., Enns C. A., etal. Assignment of the gene for human melanoma-associated antigen p97 to chromosome 3 ... Rose T. M., Plowman G. D., Teplow D. B., etal. Primary structure of the human melanoma-associated antigen p97 ( ...
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e (Cluster of Differentiation 66e), is a ... 2001). "Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells". J. Biol. Chem. 276 ( ... CEACAM5, CD66e, CEA, carcinoembryonic antigen related cell adhesion molecule 5. External IDs. HomoloGene: 128801 GeneCards: ... Oikawa S, Nakazato H, Kosaki G (1987). "Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence". ...
The protein also carries the Jr(a) antigen, which defines the Junior blood group system.[9] ...
van Rhenen A., van Dongen G. A., Kelder A., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination ...
"Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin". Molecular and ...
Ebert LM, McColl SR (2002). "Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes ... This receptor has been shown to be important for B-lineage maturation and antigen-driven B-cell differentiation, and it may ... dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens". J. Immunol. 167 (11): ...
It is also called Lewis x and SSEA-1 (stage-specific embryonic antigen 1) and represents a marker for murine pluripotent stem ... CD15 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) ... CD15 (3-fucosyl-N-acetyl-lactosamine) is a cluster of differentiation antigen - an immunologically significant molecule. CD15 ...
A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... antigen processing and presentation of exogenous peptide antigen via MHC class II. ... antigen binding. • transmembrane signaling receptor activity. • MHC class II protein binding. Cellular component. • membrane. • ...
CD34 • CD35 • CD36 • CD37 • CD38 • CD39 • CD40 • CD41 • CD42 (a, b, c, d) • CD43 • CD44 • CD45 • CD46 • CD47 • CD48 • CD49 (a, ... CD97 antigen je protein koji je kod ljudi kodiran CD97 genom.[1][2][3] ... 2001). "Tissue distribution of the human CD97 EGF-TM7 receptor". Tissue Antigens 57 (4): 325-31. PMID 11380941. doi:10.1034/j. ... "Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of ...
"Entrez Gene: ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)".. *^ May, K. E.; Villar, J.; Kirtley, S.; ... CD61+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ...
L-selectins: L-selectins are constitutively expressed on some leukocytes, and are known to bind GlyCAM-1, MadCAM-1 and CD34 as ... and is independent of specific cellular antigens. Cytokines released in the initial immune response induce vasodilation and ...
"Direct association of adenosine deaminase with a T cell activation antigen, CD26". Science. 261 (5120): 466-9. doi:10.1126/ ...
B cells can present antigens to a specialized group of helper T cells called TFH cells. If an activated TFH cell recognizes the ... Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help". Journal of Immunology. 149 (12): ... It binds to CD40 (protein) on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In ... Grewal, IS; Xu, J; Flavell, RA (7 December 1995). "Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand". ...
... and dendritic cells which present antigens to activate components of the adaptive immune system such as T-cells and B-cells.[51 ... "In vitro generation of type-II pneumocytes can be initiated in human CD34(+) stem cells". Biotechnology Letters. 38 (2): 237- ...
antigen processing and presentation of peptide antigen via MHC class I. • antigen processing and presentation of exogenous ... antigen processing and presentation of exogenous peptide antigen via MHC class I. • lipoprotein transport. • negative ... peptide antigen via MHC class I, TAP-dependent. • platelet degranulation. • MyD88-dependent toll-like receptor signaling ...
Primarily, the VCAM-1 protein is an endothelial ligand for VLA-4 (Very Late Antigen-4 or integrin α4β1) of the β1 subfamily of ...
... uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate (англ.) // Blood (англ ...
In addition to aiding with cytotoxic T cell antigen interactions the CD8 co-receptor also plays a role in T cell signaling. The ... the CD8 co-receptor plays a role in T cell signaling and aiding with cytotoxic T cell antigen interactions. ... This affinity keeps the T cell receptor of the cytotoxic T cell and the target cell bound closely together during antigen- ... Once the T cell receptor binds its specific antigen Lck phosphorylates the cytoplasmic CD3 and ζ-chains of the TCR complex ...
antigen binding. • virus receptor activity. • protein binding. • transmembrane signaling receptor activity. • identical protein ...
CD34 • CD35 • CD36 • CD37 • CD38 • CD39 • CD40 • CD41 • CD42 (a, b, c, d) • CD43 • CD44 • CD45 • CD46 • CD47 • CD48 • CD49 (a, ... 1996). "CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human ...
CD74 (англ. HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain) - мембранный белок ... II histocompatibility antigen gamma chaingamma chain of class II antigensIiHLA-DR antigens-associated invariant chainIa antigen ... Riberdy J.M., Newcomb J.R., Surman M.J., Barbosa J.A., Cresswell P. HLA-DR molecules from an antigen-processing mutant cell ... Machamer C.E., Cresswell P. Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens (англ.) // ...
1997). "The Oka blood group antigen is a marker for the M6 leukocyte activation antigen, the human homolog of OX-47 antigen, ... 1992). "Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse ... Kasinrerk W, Fiebiger E, Stefanová I, Baumruker T, Knapp W, Stockinger H (1992). "Human leukocyte activation antigen M6, a ... Ok blood group system at BGMUT Blood Group Antigen Gene Mutation Database at NCBI, NIH ...
CD34 • CD35 • CD36 • CD37 • CD38 • CD39 • CD40 • CD41 • CD42 (a, b, c, d) • CD43 • CD44 • CD45 • CD46 • CD47 • CD48 • CD49 (a, ... 1991). „Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow". Blood. 78 (1): 30-7. PMID ... 2003). „Signal transduction-associated and cell activation-linked antigens expressed in human mast cells". Int. J. Hematol. 75 ...
All MeSH CategoriesChemicals and Drugs CategoryBiological FactorsBiomarkersAntigens, DifferentiationAntigens, CDAntigens, CD34 ... All MeSH CategoriesChemicals and Drugs CategoryBiological FactorsAntigensAntigens, SurfaceAntigens, DifferentiationAntigens, CD ... Antigens, CD34. Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date ...
OMIM: HEMATOPOIETIC PROGENITOR CELL ANTIGEN CD34; CD34*Gene Ontology: Cd34 *Mouse Phenome DB: Cd34 *UCSC: Chr.1:194,938,821- ... Cd34. CD34 antigen. Gene nomenclature, locus information, and GO, OMIM, and PMID associations are updated daily from MGI ... Researchers interested in Cd34 are also interested* in Pecam1 Efnb2 Angpt1 Krt14 Cd44 Shh Acta2 Tie1 Myb Krt15 ... Ensembl: ENSMUSG16494 (Cd34)*NCBI: 12490, 50886*Vega: OTTMUSG50886*CCDS: 15640, 15640.1, 48490* ...
CD34 protein is involved in differentiating HPCs into certain types of neurons. Also useful for studying endothelial cells, ... Research proven mouse monoclonal CD34 antibody. Excellent marker for hematopoietic progenitors and stem cells. ... CD34 may also stimulate proportions of adult human HSCs to differentiate into full-fledged neurons. This may open new ... In tumors, CD34 is found in alveolar soft part sarcoma, preB-ALL (positive in 75%), AML (40%), AML-M7 (most), ...
Density of the microvessels was being evaluated basing on the expression of the antigen CD34 and CD105. Evaluation of the ... Microtissue density prognostic factor evaluation based on antigens CD34 and CD 105 in ovarian cancer patients ... The subject of this publication is to find the answer to a question whether the practical usage of the CD34 and CD 105 as a ... The anti-CD34 reacts with the largest number of endoepithelial cells. The second group constitutes the antibodies that ...
Dye Efflux Studies Suggest That Hematopoietic Stem Cells Expressing Low or Undetectable Levels of CD34 Antigen Exist in ... Like the murine SP cells, both human and rhesus SP cells are primarily CD34-negative and lineage marker-negative. In vitro ... These studies suggest the existence of a hitherto unrecognized population of hematopoietic stem cells that lack the CD34 ... coincident with their conversion to a CD34-positive phenotype. ...
Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins ...
CD34" by people in this website by year, and whether "Antigens, CD34" was a major or minor topic of these publications. ... "Antigens, CD34" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "Antigens, CD34" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Antigens, CD34". ...
A) Splenocytes from mice injected with transduced CD34 were pooled and stimulated ex vivo with MART-1 peptide (1μg/mL) and ... 2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733. ... 1A) (33, 34). F5 MART-1 is an improved MART-1-specific TCR displaying enhanced affinity to the antigen and was provided by the ... Antigen-specific human T cells have been developed in vitro using OP9 stromal cells expressing the human Notch ligand Delta- ...
CD34, CD38, CD117, and CD123; aberrant expression of lymphoid or mature myelomonocytic antigens on CD34(+) myeloblasts; and ... Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post ... With recent advances in multi-color flow cytometry immunophenotypic analysis, a CD34(+) progenitor-focused 7-color assay was ... a core panel of markers was selected for final assessment that included increased total CD34(+) myeloblasts; decreased stage I ...
Recombinant Human Hematopoietic progenitor cell antigen CD34 is produced by our Mammalian expression system and the target gene ... Recombinant Human Hematopoietic progenitor cell antigen CD34 is produced by our Mammalian expression system and the target gene ... Human CD34 is high glycosylated type I transmembrane protein, and it could act as a scaffold for the attachment of lineage ... CD34 is found on multipotent precursors, bone marrow stromal cells, embryonic fibroblasts, vascular endothelia, as well as some ...
CD34 Molecule, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene ... Hematopoietic progenitor cell antigen CD34) ELISA and Immunotag™ Hematopoietic progenitor cell antigen CD34 ELISA Kit ... View all 43 R&D Systems CD34 (CD34) Products. *View all R&D Systems CD34 (CD34) Proteins and Enzymes*Recombinant Human CD34 ... GeneCards Summary for CD34 Gene CD34 (CD34 Molecule) is a Protein Coding gene. Diseases associated with CD34 include Spindle ...
CD34 Molecule, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene ... Hematopoietic progenitor cell antigen CD34) ELISA and Immunotag™ Hematopoietic progenitor cell antigen CD34 ELISA Kit ... GeneCards Summary for CD34 Gene CD34 (CD34 Molecule) is a Protein Coding gene. Diseases associated with CD34 include Spindle ... Animal Models for CD34 Gene. MGI Knock Outs for CD34:. * Cd34 Cd34,tm1Szk, ...
CD34, also known as gp105-120, is a highly glycosylated type I monomeric sialomucin-like glycophophoprotein with an approximate ... Antigen References 1. Garlanda C, et al. 1997. Eur. J. Cell Biol. 73:368.. 2. Brown J, et al. 1991. Int. Immunol. 3:175.. 3. ... CD34 is expressed on hematopoietic progenitors, endothelial cells, brain, and testis. CD34 mediates cell adhesion and ... Antigen Details Structure Type I monomeric glycophophoprotein with an approximate molecular weight of 105-120 kD. Distribution ...
CD34, also known as gp105-120, is a type I monomeric sialomucin-like glyco-phosphoprotein with an approximate molecular weight ... Antigen Details Structure 105-120 kD single chain mucin-like glycoprotein Distribution Hematopoietic stem/progenitor cells, ... Based on different sensitivities, four groups of epitopes of CD34 have been described. CD34 mediates cell adhesion and ... CD34, also known as gp105-120, is a type I monomeric sialomucin-like glyco-phosphoprotein with an approximate molecular weight ...
Using next generation sequencing we deduced the transcriptome of HCMV latently infected CD14 (+) and CD34 (+) cells in ... Antigens, CD34* * Cells, Cultured * Cytomegalovirus / genetics * Cytomegalovirus / metabolism* * Cytomegalovirus Infections / ... Using next generation sequencing we deduced the transcriptome of HCMV latently infected CD14 (+) and CD34 (+) cells in ... The parameters involved in human cytomegalovirus (HCMV) latent infection in CD14 (+) and CD34 (+) cells remain poorly ...
Compare CD34 ELISA Kits from XpressBio from leading suppliers on Biocompare. View specifications, prices, citations, reviews, ... The ELISA (enzyme-linked immunosorbent assay) is a well-established antibody-based tool for detecting and quantifying antigens ...
Myeloid antigen expression was found in 25% of patients. Expression of myeloid antigen in B-lineage leukemia was 27%, and in T- ... In the whole cohort of patients we did not find a significant association between myeloid antigen expression and survival, ... In conclusion, in the Indonesian ALL population, in particular, myeloid antigen-expressing T-ALL patients had a higher chance ... The clinical relevance of myeloid antigen expression in childhood ALL is controversial. In Indonesian patients, no data were ...
Pecci, A., Travaglino, E., Klersy, C., & Invernizzi, R. (2003). Apoptosis in relation to CD34 antigen expression in normal and ... Pecci A, Travaglino E, Klersy C, Invernizzi R. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic ... Pecci, A, Travaglino, E, Klersy, C & Invernizzi, R 2003, Apoptosis in relation to CD34 antigen expression in normal and ... We investigated the degree of apoptosis in MDS BM and its differences from normal marrow in relation to CD34 antigen expression ...
Mouse Monoclonal CD34 antibody [SPM610]. Validated in WB, ICC/IF, IHC-P. Tested in Human, Rat. - professional antibody ... which is identified as CD34 (VI international workshop on human differentiation antigens). Its expression is a hallmark for ... Cd34 Molecule,Cd34 Background The protein encoded by this gene may play a role in the attachment of stem cells to the bone ... CD34 is a marker of choice for staining blasts in acute myeloid leukemia. In addition, it is expressed by soft tissue tumors, ...
Rat Monoclonal CD34 antibody [MEC14.7] (Low endotoxin, azide free). Validated in ICC/IF, IHC-P, FACS, IP, IHC. Tested in Human ... Antigen Species Mouse Immunogen T-end.1, a pMT transformed endothelial cell line. ... There are currently no reviews for CD34 antibody [MEC14.7] (Low endotoxin, azide free) (GTX42057). Be the first to share your ... FACS analysis of WEH1 cells using GTX42057 CD34 antibody [MEC14.7] (Low endotoxin, azide free). ...
... ssPB-CD34), and of patients or healthy volunteers after mobilization (mPB-CD34) were investigated. ssPB-CD34+ cells contain a ... Functional characterization of human CD34+ cells that express low or high levels of the membrane antigen CD111 (nectin 1) *G ... ssPB-CD34), and of patients or healthy volunteers after mobilization (mPB-CD34) were investigated. ssPB-CD34+ cells contain a ... These results indicate that mPB-CD34+ cells have different phenotypic and functional properties from ssPB-CD34+ cells. This may ...
Shop a large selection of products and learn more about CD34 Mouse anti-Human, FITC, Clone: CS37, Invitrogen 100 Tests; FITC ... CD34 is thought to have a role in presenting carbohydrate ligands to selectins. The intracellular chain of the CD34 antigen is ... CD34 is a stem cell marker although its expression on human hematopoietic stem cells is reversible. CD34 may serve as a surface ... CD34 is possibly an adhesion molecule with a putative role for mediating the attachment of stem cells to the bone marrow ...
Antigens, CD34. abacavir. Treatment Naive. Additional relevant MeSH terms: Infection. HIV Infections. Lentivirus Infections. ...
leukocyte common antigen (CLA; CD45: %), and stem/progenitor (CD34: %; CD73: , and CD105: %) markers immediately postthaw. ... the expressions of antigens associated with myeloid (CD19), stem/progenitor (CD34), preadipocyte (CD36), hematopoietic (CLA; ... Compared to the immunophenotype of freshly thawed cells, the expression of antigens associated with all of the lineages ... Throughout a one-week period, adipose-derived SVF cells within the ObaGel constructs continued to express surface antigens ...
Human and Murine HSCs Express CD34. The cell-surface marker, CD34, was first identified as a hematopoietic cell-surface antigen ... Kinetics of engraftment of CD34− and CD34+ cells from mobilized blood differs from that of CD34− and CD34+ cells from bone ... Identification of Murine CD34−HSCs. In 1996, Osawa et al. first reported on CD34− HSCs. In that study, they isolated pure CD34 ... reported that murine BM Lin−CD34− and Lin−CD34+ cells could generate long-term engraftment, but that CD34+ cells were 100-fold ...
Device: CliniMACS® CD34 Reagent System Drug: Fludarabine Drug: Melphalan Drug: anti-thymocyte globulin (rabbit) Drug: Rituximab ... Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation. The safety and scientific ... Device: CliniMACS® CD34 Reagent System The stem cells from the haplo-identical donor will be purified by a procedure called ... A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The ...
Buy our Recombinant Human CD34 protein. Ab182830 is a protein fragment produced in Escherichia coli and has been validated in ... CD34 molecule. *CD34_HUMAN. *Cluster designation 34. *Hematopoietic progenitor cell antigen CD34 ...
Identity of circulating EPCs defined by surface antigens using FACS. CD34+KDR+(CD133+) ... Dessapt et al found lower levels of CD34+ and CD34+CD133+ cells in type 1 diabetic patients with, compared with those without, ... Rather, CD34+ cells in the CD45- fraction eventually co-expressing other endothelial markers (e.g. CD31 and CD146), are ... Type 1 diabetes causes early EPC dysfunction that is quite similar to that observed in type 2 diabetes [49]. Circulating CD34+ ...
Rat monoclonal CD34 antibody [MEC 14.7] validated for WB, IP, ELISA, IHC, Flow Cyt, ICC/IF and tested in Mouse. Referenced in ... Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. Staining with ... Anti-CD34 antibody [MEC 14.7] (ab8158) at 1 µg/ml + Mouse Lung Membrane Tissue Lysate (ab171830) at 50 µg. Secondary. Goat Anti ... IHC image of CD34 staining in Mouse brain FFPE section, performed on a BondTM system using the standard protocol B. The section ...
There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J ... Barth PJ, Schenck zu Schweinsberg T, Ramaswamy A, Moll R. CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts ... Figure 3 Two cases (left and right rows of pictures) of stromal cell expression of CD34 and vimentin. Healthy breast tissue ... Nasuprot tomu, stroma svih invazivnih i duktalnih karcinoma dojke in situ nije sadržavala fibroblaste pozitivne na CD34. Većina ...
  • CD34 (CD34 Molecule) is a Protein Coding gene. (
  • CD34 is possibly an adhesion molecule with a putative role for mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. (
  • CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes . (
  • Since different patterns of glycosylation of the molecule are seen with different cell types, this might explain the wide range of CD34 molecular mass (from 75-85 kDa to 120 kD). (
  • Clone REAL487 is an antibody fragment derived from the full CD34 antibody molecule. (
  • CD34 is an ~105 - 120 kDa type 1 transmembrane glycoprotein expressed on the surface of most human hematopoietic stem and progenitor cells (HSPCs), as well as on endothelial cells and some tumor cell lines. (
  • On immunohistochemical study, tumor cells exhibited characteristics of mesenchymal and endothelial origin, i.e., strong to moderate immune reactivity against vimentin, factor VIII-related antigen (F8RA), Ulex europaeus agglutinin type 1 lectin (UEA-1), and CD 34, but not against keratin, epithelial membrane antigen (EMA) or S-100 protein (S100). (
  • This antibody does not detect Human CD34 and is an execellent tool for marking host derived endothelial cells/vasculature in human cancer xenografts on mouse. (
  • CD34 Antibody MEC 14.7 (NB600-1071) is a useful reagent for identification and characterization of capillary endothelial cells. (
  • 27. The isolated or purified population of mammalian hematopoietic stem cells of claim 20, wherein the purified population of mammalian endothelial stem cells that are Lin − Sca + CD34 + constitute 15-100% of the total population. (
  • The CD34 antigen is a single chain transmembrane glycoprotein, expressed on human hematopoitetic stem and progenitor cells, endothelial progenitor cells, vascular endothelial cells, embryonic fibroblasts, and some cells in fetal and adult nervous tissue. (
  • CD34 antibodies can be used for studies of hematopoiesis and nonhematopoiectic stem cells, phenotyping of hematopoietic stem cells, and studies on phenotyping of hematologic malignancies, endothelial cells, and endothelial progenitor cells (EPCs). (
  • CD34 antibodies can be used for studies of hematopoiesis and nonhematopoiectic stem cells, phenotyping of endothelial cells, and endothelial progenitor cells (EPCs), hematopoietic stem cells, and studies on phenotyping of hematologic malignancies, e.g. the identification of blasts in leukemia. (
  • Fibroblasts and endothelial cells were immunostaining by CD34. (
  • There is some agreement that the cell surface antigens CD133 and vascular-endothelial growth factor receptor 2, along with LDL uptake and lectin binding, may be used to identify these cells. (
  • CD34 is found on multipotent precursors, bone marrow stromal cells, embryonic fibroblasts, vascular endothelia, as well as some populations of mesenchymal stem cells, and tumor cell lines, and it is a common marker for diverse progenitors. (
  • CD34 may serve as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation, and proliferation of hematopoietic stem cells and other progenitors. (
  • CD34 was first identified as an antigen expressed on hematopoietic progenitors, and has since been extensively used as a marker to isolate cells capable of hematopoietic cell engraftment. (
  • In addition to expression on hematopoietic progenitors, CD34 is expressed on some populations of mesenchymal stem cells, tumor cell lines, and by vascular endothelia in the adult. (
  • Therefore, we analyzed expression of CXCR-4 on mobilized normal CD34 + progenitors and leukemic cells. (
  • In accordance with the immunofluorescence data, CD34 + progenitors efficiently migrated across endothelium in response to SDF-1 containing conditioned medium from the stromal cell line MS-5. (
  • We conclude that CXCR-4 is expressed on CD34 + cells including more primitive, pluripotent progenitors, and may therefore play a role in the homing of hematopoietic stem cells. (
  • Mast cells were immunoreactive for epithelial membrane antigen (EMA) and S-100 protein. (
  • The panendotelial antibodies targeted against such markers as CD34 are used most frequently in cancer vessel evaluation. (
  • The second group constitutes the antibodies that agglomerate with the antigens characteristic for proliferous endoepithelial cells. (
  • This antibody (clone SA376A4) is useful for staining mouse CD34 + hematopoietic stem cell but it does not stain NIH-3T3 cells and the staining of Bend.3 cells is dimmer compared to other mouse CD34 antibodies, probably due to this antibody recognizes a different epitope than the other monoclonal antibodies. (
  • On the basis of differential sensitivity to degradation by specific enzymes, epitopes of monoclonal antibodies to CD34 are classified into three main categories, class I, class II and class III. (
  • 7. A process as claimed in claim 1 wherein the tumor cells are from breast carcinoma, lung carcinoma, or neuroblastoma, and the antibody composition contains antibodies specific for antigens expressed on the surface of cells from breast carcinoma, lung carcinoma, or neuroblastoma. (
  • Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. (
  • The pairing of living organ donors who want to give an organ to someone with whom they are antigenically mismatched with other pairs of donors and recipients who share appropriate antigens, antibodies, and blood types. (
  • The following product was used in this experiment: CD34 Monoclonal Antibody (4H11), PE, eBioscience from Thermo Fisher Scientific, catalog # 12-0349-42, RRID AB_1548680. (
  • Description: The 4H11 monoclonal antibody reacts with human CD34, also known as mucosialin. (
  • The monoclonal antibody clone AC136 detects a class III epitope of the CD34 antigen. (
  • Clone AC136 has a similar specifity as the CD34 monoclonal antibody clone 8G12 (HPCA-2). (
  • After desirable blood-forming cells with this antigen are removed from the patient's blood, high-dose chemotherapy, monoclonal antibody therapy, or radiation may be used to purge the marrow of diseased cells. (
  • Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor-mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti-HPCA-1. (
  • Human CD34 is high glycosylated type I transmembrane protein, and it could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. (
  • This antibody recognizes a carbohydrate epitope on a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34 (VI international workshop on human differentiation antigens). (
  • CD34 is a highly glycosylated, monomeric, 111-115 kDa surface protein that is present on many stem cell populations. (
  • The intracellular chain of the CD34 antigen is a site of phosphorylation by activated protein kinase C suggesting a putative role in signal transduction. (
  • CD34 is a highly glycosylated monomeric 111-115kDa surface protein, which is present on many stem cell populations. (
  • CD34 is a highly glycosylated monomeric with a molecular weight range of 111-115 kDa surface protein that is present on many stem cell populations. (
  • Hematopoietic progenitor cell antigen CD34 also known as CD34 antigen is a protein that in humans is encoded by the CD34 gene. (
  • The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. (
  • This MAb recognizes a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34. (
  • CD34 is a transmembrane phosphoglycoprotein protein encoded by the CD34 gene in humans, mice, rats and other species. (
  • CD34 belongs to a protein family which also includes endoglycan and podocalyxin. (
  • The CD34 protein is a hematopoietic progenitor cell antigen that occurs in a variety of mesenchymal tumors. (
  • CD34 antibody was purified from mouse ascitic fluids by protein-A affinity chromatography. (
  • CD5 specifically interacts with CD72 antigen (CD72), a cell-surface protein exclusively expressed in B cells. (
  • Hematopoietic progenitor cell antigen CD34/CD34 (C-6His)-Human-Novoprotein Scientific Inc. (
  • Recombinant Human Hematopoietic progenitor cell antigen CD34 is produced by our Mammalian expression system and the target gene encoding Ser32-Thr290 is expressed with a 6His tag at the C-terminus. (
  • CD34 is a type I transmembrane glycophosphoprotein expressed by hematopoietic stem/progenitor cells (HSCs). (
  • The anti-CD34 reacts with the largest number of endoepithelial cells. (
  • Like the murine SP cells, both human and rhesus SP cells are primarily CD34-negative and lineage marker-negative. (
  • Although rhesus SP cells do not initially possess any hematopoietic colony-forming capability, they acquire the ability to form colonies after long-term culture on bone marrow stroma, coincident with their conversion to a CD34-positive phenotype. (
  • These studies suggest the existence of a hitherto unrecognized population of hematopoietic stem cells that lack the CD34 surface marker classically associated with primitive hematopoietic cells. (
  • These autologous T cells have been generated either by ex vivo manipulation of antigen-specific T cells with cytokines or by genetically engineering T cells to exhibit strong antitumor responses ( 5 - 16 ). (
  • Recent clinical studies have used chimeric antigen receptors to modify T cells genetically to target and deplete leukemia cells ( 5 , 6 ). (
  • 17 ) transduced autologous T cells ex vivo with a vector expressing a natural T-cell receptor (TCR) specific for the melanoma-associated antigen recognized by T-cells 1 [MART-1(26-35)] epitope and reintroduced them into patients, resulting in tumor regression in two of the 15 subjects ( 17 ). (
  • Some of these limitations could be circumvented by the use of genetically modified human hematopoietic stem cells (hHSC) to generate mature and functional antigen-specific T cells. (
  • Antigen-specific human T cells have been developed in vitro using OP9 stromal cells expressing the human Notch ligand Delta-like 1 ( 25 , 26 ). (
  • C57BL/6 mouse bone marrow cells were stained with anti-mouse Lineage Cocktail Pacific Blue™ and CD34 (clone SA376A4) Alexa Fluor® 647 (top) or rat IgG2a, κ Alexa Fluor® 647 isotype control (bottom). (
  • CD34 mediates cell adhesion and lymphocytes homing through binding to L-selectin and E-selectin ligands, and mediates the attachment of stem cells to the extracellular matrix or stromal cells. (
  • Mouse CD34 transfected cells. (
  • CD34 is a commonly used marker for identifying human hematopoietic stem/progenitor cells. (
  • The parameters involved in human cytomegalovirus (HCMV) latent infection in CD14 (+) and CD34 (+) cells remain poorly identified. (
  • Using next generation sequencing we deduced the transcriptome of HCMV latently infected CD14 (+) and CD34 (+) cells in experimental as well as natural latency settings. (
  • FACS analysis of WEH1 cells using GTX42057 CD34 antibody [MEC14.7] (Low endotoxin, azide free). (
  • The phenotype and functions of CD34 + cells isolated from peripheral blood (PB) of steady-state healthy volunteers (ssPB-CD34), and of patients or healthy volunteers after mobilization (mPB-CD34) were investigated. (
  • ssPB-CD34 + cells contain a lymphoid cell population that co-express T or B cell markers, while mPB-CD34 + cells lack this population. (
  • After 5-day culture, significantly higher levels of expansion in cell, CD34 + cell, and HPP-CFC numbers were induced in ssPB-CD34 + cells, as compared to mPB-CD34 + cells. (
  • It was found that ssPB-CD34 + cells retained the potential to reconstitute human bone marrow (BM), as well as thymus implanted in SCID animals. (
  • In contrast, only very low levels of reconstitution were detected in human hematopoietic tissues injected with cultured mPB-CD34 + cells. (
  • The loss of B cell reconstitution potential of mPB-CD34 + cells was shown to be induced in a time-dependent manner during culture. (
  • These results indicate that mPB-CD34 + cells have different phenotypic and functional properties from ssPB-CD34 + cells. (
  • CD34 is a stem cell marker although its expression on human hematopoietic stem cells is reversible. (
  • Further, CD34 could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. (
  • The frequency of acute lymphoblastic leukemia (ALL) patients expressing myeloid antigens on their ALL cells varies between 5 and 36% in several different studies. (
  • When MDS and normal CD34-negative cell populations were compared, a greater AR in MDS CD34-negative cells was found, while no statistical difference in AR resulted from the comparison between MDS and normal CD34-positive cell populations. (
  • Recent data have suggested that human CD34 − hematopoietic stem cells (HSCs) exist, challenging the concept that HSCs necessarily and exclusively express the CD34 antigen. (
  • In mice, quiescent HSCs have been shown to be mostly CD34 − , but as a consequence of 5-fluorouracil treatment or cytokine stimulation, differentiate into CD34 + cells. (
  • These SP cells are mostly CD34 − , highly enriched for long-term repopulating cells, and durably engraft in sublethally irradiated non-obese diabetic/severe combined immunodeficient mice. (
  • The cell-surface marker, CD34, was first identified as a hematopoietic cell-surface antigen using the early human myeloblastic cell line KG-1a [ 6 , 7 ], which highly expresses CD34 and displays a strong potential for myeloid colony-forming cells [ 8 ]. (
  • After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device. (
  • Tissue, cells or virus corresponding to Mouse CD34. (
  • A concurrent patient group meeting eligibility but not receiving CD34+ cells will be evaluated similar to the treated group to assess the rate of significant spontaneous improvement in cardiac function without CD34+cell infusion. (
  • The presence of CD34 on non-hematopoietic cells in various tissues has been linked to progenitor and adult stem cell phenotypes. (
  • CD34 is expressed in roughly 20% of murine hematopoietic stem cells, [21] and can be stimulated and reversed. (
  • BACKGROUND: Rh phenotype is an extremely rare condition characterized by no expression of Rh antigens at the surface of red blood cells. (
  • CD34 expression is a hallmark for identifying pluripotent hematopoietic stem or progenitor cells. (
  • CD34 was first described on hematopoietic stem cells independently by Civin et al. (
  • Due to these historical and clinical associations, CD34 expression is almost ubiquitously related to hematopoietic cells however it is actually found on many other cell types as well. (
  • and, the hematopoietic stem cells are Lin − Sca + c-kit + and are derived from postnatal mammals wherein the hematopoietic stem cells are Lin − Sca + CD34 + , and are human hematopoietic stem cells. (
  • The antigen is absent on fully differentiated hematopoietic cells such as normal peripheral blood lymphocytes, monocytes, granulocytes, erythrocytes, and platelets. (
  • However, the complicated culturing conditions for in vitro expansion of MSCs, together with the required HLA (human histocompatibility leukocyte antigen) matching for hUCB transplantation between donor and recipient, may limit the clinical application of these cells. (
  • The chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR-4 (fusin, LESTR) are likely to be involved in the trafficking of hematopoietic progenitor and stem cells, as suggested by the reduced bone marrow hematopoiesis in SDF-1-deficient mice and the chemotactic effect of SDF-1 on CD34 + progenitor cells. (
  • By flow cytometry, CXCR-4 was found to be expressed in significant amounts on circulating CD34 + hematopoietic progenitor cells, including more primitive subsets (CD34 + /CD38 − and CD34 + /Thy-1 + cells). (
  • 13 This concept is supported by the finding that SDF-1 is chemotactic for CD34 + hematopoietic progenitor cells from bone marrow and peripheral blood. (
  • The CD117 antigen is expressed on very few normal bone marrow cells. (
  • The majority of CD117+ marrow cells co-express CD34. (
  • In order to broad- en the array of tools for cell-based autologous therapies, we iso- lated a novel renewable stem cell population from the adult testes that has characteristics of MSCs, termed gonadal stem cells (GSCs). (
  • Enhancing the function of CD34(+) cells by targeting plasminogen activator inhibitor-1. (
  • Using gene array studies, we examined CD34(+) cells isolated from a cohort of longstanding diabetic individuals, free of microvascular complications despite suboptimal glycemic control, and found that the cells exhibited reduced transcripts of both TGF-β1 and PAI-1 compared to age, sex, and degree of glycemic control-matched diabetic individuals with microvascular complications. (
  • CD34(+) cells from diabetic subjects with microvascular complications consistently exhibited higher PAI-1 mRNA than age-matched non-diabetic controls. (
  • Immunohistochemically, the tumor cells exhibit positivity for vimentin and CD34. (
  • Both mononuclear and bizarre lesional cells expressed strongly and diffusely vimentin and CD34. (
  • Professional antigen presenting cells (APC), i.e., dendritic cells (DC), monocytes/macrophages, and B lymphocytes, are critically important in the recognition of an invading pathogen and presentation of antigens to the T cell-mediated arm of immunity. (
  • We postulate that host control of HHV-8 infection and development of KS is linked to T cell interactions with HHV-8 infected, professional antigen presenting cells (APC), i.e., dendritic cells (DC), monocytes/macrophages, and B lymphocytes. (
  • CD34 is a single chain transmembrane glycoprotein which is selectively expressed on human lymphoid and myeloid hemapoietic progenitor cells. (
  • Anti-human CD34 mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human CD34 amino acids 32-290 purified from E. coli. (
  • The matching of histocompatibility antigens that differentiate one person's cells from another's helps prevent rejection of donated tissues. (
  • In leukapheresis stem cells are identified by a cell surface antigen called CD34. (
  • We show that activation of endogenous Notch signaling in human CD34 + CD38 - cord blood precursors with immobilized Delta-1 in serum-free cultures containing fibronectin and hematopoietic growth factors inhibited myeloid differentiation and induced a 100-fold increase in the number of CD34 + cells compared with control cultures. (
  • Immobilized Delta-1 also induced a multifold expansion of cells with the phenotype of common lymphoid precursors (CD34 + CD7 + CD45RA + ) and promoted the development of cytoplasmic CD3 + T/NK cell precursors. (
  • We evaluated multiple signaling pathways in antigen-defined subpopulations in primary AML cells with FLT3-ITD mutations. (
  • Functionally, embryonic antigen-presenting cells (APCs) are able to phagocytose antigen, to up-regulate costimulatory molecules upon culture, and to efficiently stimulate T cells in a mixed lymphocyte reaction. (
  • At 7 wk EGA, some epidermal cells already express HLA-DR, but not CD1a or Lag antigen, a component of Birbeck granules, which appear at ∼12 wk EGA ( 16 , 19 ). (
  • Flow cytometry analysis (surface staining) of CD34+ cells in human peripheral blood with anti-human CD34 (4H11[APG]) APC. (
  • Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. (
  • Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three-dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk-L. Stem Cells Dev. (
  • CyTOF and conventional FCM yielded comparable results on LSC phenotypes defined by CD45, CD34, CD38, CD123, and CD99. (
  • Each antibody is crafted with care according to rigorous protocols for immunogen design and preparation, presentation to host animal, and high-affinity purification against the antigen. (
  • Clone 8G12 does not recognize rhesus macaque CD34. (
  • This epitope is different than the one recognized by the clone used in the CD34 MicroBead Kits. (
  • CD34 is a cluster of differentiation first described independently by Civin et al. (
  • CD34 derives its name from the cluster of differentiation protocol that identifies cell surface antigens. (
  • CD34 antibody has been tested by ELISA, Western blot analysis, ICC/IF and Flow cytometry to assure specificity and reactivity. (
  • Independent of location, most GISTs express the CD34 antigen (70-78%) and the CD117 (72-94%) antigen. (
  • The CD117 antigen is the 145 kDa protooncogene c-kit. (
  • CD34 may also stimulate proportions of adult human HSCs to differentiate into full-fledged neurons. (
  • CD34 staining of human tonsil tissue. (
  • In this review, current concepts on murine and human CD34 − HSCs and their relationship with CD34 + HSCs are discussed. (
  • [ citation needed ] Human HSCs express the CD34 marker. (
  • 2450-2457, 1996) that PR1, a human-lymphocyte-antigen (HLA)-A2.1-restricted peptide from proteinase 3, could be used to elicit CTLs from normal individuals. (
  • CD34, CD44, human nerve growth factor receptor have been reported in some cases. (
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. (
  • CD34 is a marker of choice for staining blasts in acute myeloid leukemia. (
  • 120 (4):501-11 Enrichment for living murine keratinocytes from the hair follicle bulge with the cell surface marker CD34. (
  • CD34 expression is significantly associated with both FLT3 ITD mutation and cMPL expression which could be used as a marker for low survival. (
  • In this study, rats receiving intracerebral peripheral blood hematopoietic stem cell (CD34 + ) (PBSC) transplantation showed much more improvement in neurological function after chronic cerebral ischemia in comparison with vehicle-treated control rats. (
  • In contrast, CD34 + leukemic cell lines (KG1, KG1a, Kasumi-1, MOLM-1) expressed low levels or were negative for CXCR-4, and did not migrate. (
  • Elknerová K, Lacinová Z, Soucek J, Marinov I, Stöckbauer P: Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. (
  • The aim of this study was the evaluation of intracellular signaling in antigen-defined stem/progenitor cell subsets in primary AML. (
  • Diseases associated with CD34 include Spindle Cell Lipoma and Dermatofibrosarcoma Protuberans . (
  • Diseases associated with CD34 dysfunction include dermatofibrosarcoma and neurofibroma. (
  • The clinical relevance of myeloid antigen expression in childhood ALL is controversial. (
  • Myeloid antigen expression was found in 25% of patients. (
  • No association was found between myeloid antigen expression and clinical or biological features. (
  • Moreover, the clinical relevance of myeloid antigen expression in childhood ALL as a prognostic factor remains controversial [ 5 , 8 - 12 ]. (
  • In addition, the relevance of myeloid antigen expression on both B-lineage and T-lineage ALL patients for treatment outcome was also analyzed. (
  • Because an increased incidence of myeloid antigen expression has been observed in Ph + and/or BCR-ABL + ALL, 1 6 10 it has been suggested that cytarabine-based chemotherapy regimens might be associated with high response rates in patients with the disease. (
  • Density of the microvessels was being evaluated basing on the expression of the antigen CD34 and CD105. (
  • Prognostic significance of CD34 expression in early cervical squamous cell carcinoma. (
  • CD34 expression is also found in vascular endothelium. (
  • CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions. (
  • We investigated the degree of apoptosis in MDS BM and its differences from normal marrow in relation to CD34 antigen expression. (
  • CD34 expression was significantly associated with both FLT3 ITD mutation and cMPL expression. (
  • Normal FLT3 and negative expression of CD34 and cMPL may predict a longer overall survival. (
  • Patients with leukemias that express the progenitor cell antigen CD34 and/or the P-glycoprotein (MDR1 gene product) have an inferior outcome. (
  • CD34, also known as gp105-120, is a highly glycosylated type I monomeric sialomucin-like glycophophoprotein with an approximate molecular weight of 105-120 kD, with two generated by alternative splicing. (
  • [14] [15] Conversely, under other circumstances CD34 has been shown to act as molecular "Teflon" and block mast cell, eosinophil and dendritic cell precursor adhesion, and to facilitate opening of vascular lumina. (
  • In Western blot, the reported molecular mass of CD34 is ranging from 100 to 120 kDa, apart from the HEV form (Sgp90) which is about 90 kDa. (
  • Among its related pathways are Hematopoietic cell lineage and Class I MHC mediated antigen processing and presentation . (
  • CD34 mediates cell adhesion and lymphocytes homing through binding to L-selectin and E-selectin ligands. (
  • The apoptotic rate (AR) appeared significantly higher in CD34-negative than in CD34-positive cell subsets both in myelodysplastic and in normal BM. (
  • In these animal models, murine HSCs have been demonstrated to be negative for lineage markers (Lin − ), including myeloid and B and T cell lineages, and positive for c-kit, Sca-1, and CD34 [ 1 - 5 ]. (
  • We hypothesize that identification of a graft that is at least 5/6 matched and inherited paternal antigen (IPA) targeted (i.e., cord blood grafts share one or more IPA antigens with the prospective recipient) is more important to the outcome of haplo cord transplant than the nucleated cell dose. (
  • [16] [17] Finally, recent data suggest CD34 may also play a more selective role in chemokine-dependent migration of eosinophils and dendritic cell precursors. (
  • [18] [19] Regardless of its mode of action, under all circumstances CD34, and its relatives podocalyxin and endoglycan, facilitates cell migration. (
  • Finally, recent data suggest CD34 may also play a more selective role in chemokine-dependent migration of eosinophils and dendritic cell precursors. (
  • Regardless of its mode of action, under all circumstances CD34, and its relatives podocalyxin and endoglycan, facilitates cell migration. (
  • Antigen-Driven T-Cell Selection in Patients with Cervical Cancer as Evidenced by T-Cell Receptor Analysis and Recognition of Autologous Tumor. (
  • Mice transgenic for the rat insulin promoter II gene linked to the large-T antigen of SV40 (RIPTag) develop solid β-cell tumors of the pancreas. (
  • Leukemic blasts (mostly CD34 + ) from patients with acute myeloblastic leukemia (AML) expressed variable amounts of CXCR-4, which was functionally active, as demonstrated by a positive correlation between the SDF-1-induced transendothelial migration and the cell surface density of CXCR-4 (r = 0.97). (
  • Previously, we showed that transient inhibition of TGF- β1 resulted in correction of key aspects of diabetes-induced CD34(+) cell dysfunction. (
  • This could be why T cell responses to HHV-8 antigens are not very robust. (
  • Our data suggest that CyTOF can identify functional signaling pathways in antigen-defined subpopulations in primary AML, which may provide a rationale for designing therapeutics targeting LSC-enriched cell populations. (
  • CAR is an artificial antigen receptor that mediates antibody-targeted recognition. (
  • Distinct epitope groups have been assigned to CD34 based on differences in the structure of carbohydrate groups, which affects their sensitivity to enzymatic cleavage. (
  • Evaluation of the microvessel density with CD34 and CD105 markers is not useful in forecasting survival rate and disease recurrence in patients with ovary cancer. (
  • Further studies are needed to investigate the mechanism that may correlate CD34 to both markers. (